RXi targets dermal cells with RNA delivery method

By Nick Taylor

- Last updated on GMT

Related tags: Scientific method, Pre-clinical development

RXi Pharmaceuticals has applied its sd-rxRNA to dermal cells, establishing the efficacy of the technology as it seeks to move it on to the next stage of development, a company VP told in-PharmaTechnologist.

Self delivering rxRNA (sd-rxRNA) has been developed to overcome the difficulties faced in administering RNA. RXi claims its preclinical research has demonstrated spontaneous cellular uptake into dermal cells and silencing of the targeted mRNA.

Pamela Pavco, vice president (VP) of pharmaceutical development at RXi, explained that the company is now trying to find the best candidates for particular applications. The goal is to move these candidates into non-clinical and then into clinical trials.

RXi is researching the use sd-rxRNA for both systemic and local administration.

Related topics: Ingredients, Delivery technologies

Related news

Related products

Spray Dried Powders for High Dose Drug Delivery

Spray Dried Powders for High Dose Drug Delivery

Catalent | 01-Feb-2022 | Product Presentation

This Catalent webinar will explore how spray dried particles provide an attractive, carrier-free option for highly dispersed delivery of API to deep lung...

Related suppliers

Follow us

Products

View more

Webinars